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Abstract
Differences in quality of life (QOL) of long-term survivors of aggressive or indolent subtypes of 
non-Hodgkin lymphoma (NHL) have not been frequently evaluated. We assessed these differences 
by analyzing results of a large QOL survey of long-term NHL survivors. We hypothesized that the 
incurable nature of indolent NHL would relate to worse QOL in long-term survivors while the 
potentially cured long-term survivors of aggressive lymphoma would have better QOL. We found 
that QOL was similar between the two groups. Results suggest that patients with indolent NHL are 
coping well with their disease, yet experience some overall feelings of life threat.
INTRODUCTION
The quality of life (QOL) of survivors of non-Hodgkin lymphoma (NHL) is inferior to age 
and sex matched normative controls1,2. However, there is little information about differences 
in QOL between survivors of different subtypes of NHL3,4. The QOL for survivors of 
aggressive and indolent NHL may differ because of the distinct prognosis and life 
expectancy for these two groups. Individuals with aggressive lymphoma are very sick at the 
time of initial diagnosis and may die quickly from complications, but, if in remission after 5 
years, they are considered “cured.” In contrast, indolent lymphomas are often found 
incidentally in asymptomatic individuals (i.e., enlarged lymph nodes) and may not require 
treatment for years after their diagnosis; however, with a few exceptions, there is no cure. 
Therefore, even during periods of remission survivors of advanced stage indolent lymphoma 
are living with the knowledge that their lymphoma will, in all likelihood, eventually come 
back.
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The natural history of these lymphoma types could lead to different life attitudes and 
concerns, but little is known about differences in their QOL outcomes and the psychosocial 
impact of cancer. Prior studies have not found a significant difference between the QOL of 
survivors of indolent and aggressive NHL; however, none of these reports have examined 
very long term survivors of lymphoma{Mols, 2007 #1}{Blaes, 2011 #4}{Oerlemans, 2013 
#3}. To assess the differences between those with aggressive and indolent NHL, we 
analyzed the results of a large QOL survey of long-term survivors of NHL5–11.
Another important consideration between these two groups is the matter of time since 
diagnosis; as more time passed since diagnosis, many of those with aggressive lymphoma 
would be considered cured, while those with indolent lymphoma would continue to have a 
high likelihood of relapse. Therefore, we hypothesized that the differences in QOL between 
these two populations would be greater in the group that was further out from diagnosis 
since the subgroup with indolent lymphoma would continue to live with active disease. The 
results of this work and previously published analyses of the QOL of survivors of lymphoma 
will help target the areas of need and lead to development of new interventions to improve 
the QOL in long-term and short term survivors of indolent lymphoma.
MATERIALS and METHODS
Participants and Procedures
This analysis used data from a cross-sectional study of adult NHL survivors from two 
academic medical settings (Duke University and the University of North Carolina) who were 
≥ 2 years post-diagnosis. Following Institutional Review Board approval at both sites, 886 
survivors (74% response rate) were identified through the Tumor Registries and returned a 
signed consent form and questionnaire that included items related to QOL and impact of 
cancer. Full details about the methods used to administer the surveys have been previously 
described10. Clinical data such as histology, treatment status, and disease stage were 
collected via self-report and the Tumor Registry databases. NHL histology was characterized 
as indolent or aggressive based on the coding by the International Classification of Diseases 
for Oncology-3 (ICD-0-3) codes12.
In an effort to closely evaluate differences in QOL between incurable indolent lymphoma 
and potentially cured aggressive NHL, we focused our analytic sample. To do this, we 
excluded all subjects with potentially curable stage 1–2 indolent NHL at time of diagnosis, 
unless it subsequently relapsed. Individuals with indolent lymphoma who were actively 
undergoing chemotherapy were also excluded to remove the confounding effects of 
chemotherapy on QOL. We focused on the potentially cured aggressive lymphoma 
individuals by excluding survivors currently receiving chemotherapy.
Outcome Measures
The Functional Assessment of Cancer Therapy - Lymphoma was used to assess cancer-
specific wellbeing13. It consists of a cancer-specific FACT-G measure of QOL 
(incorporating subscales related to physical, social/family, emotional, and functional well-
being) and also a 15-item lymphoma-specific symptom subscale. Although this measure was 
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originally developed for patients actively receiving treatment, it is increasingly being 
administered to post-treatment survivors. Reliability statistics for all subscales range from α 
=.77–.93. In addition, the Impact of Cancer (IOC) was used to assess survivors’ perceptions 
of the positive and negative impacts of cancer in several aspects of their well-being through 
the use of four positive and four negative subscale domains and two summary scores 
(Positive and Negative Impact)14. Reliability estimates range from α =.62–91 in this 
sample. Higher scores on the FACT-G15, FACT-LYM (composed of the FACT-G plus the 
lymphoma subscale) and IOC indicate better QOL, except for the IOC Negative Impact 
subscales and total score, for which higher scores represent greater negative impacts of 
cancer. Also, the Appraisal and Life Threat and Treatment Intensity Questionnaire 
(ALTTIQ) contributed six items (range 6–30, α =.80) to assess the extent to which cancer 
and related treatment are perceived as life-threatening and intense16.
Statistical Procedures
Descriptive statistics were used to describe the QOL outcomes for this sample overall and by 
NHL histology type (aggressive and indolent). Chi square and ANOVA were used to 
compare distributions and mean scores on the outcome variables across the two survivor 
groups. A two-way interaction of survivor status and tumor type was tested to assess 
whether QOL differences between lymphoma types were dependent on the length of time 
since diagnosis. Short- and long-term survivor status was determined by the number of years 
post-diagnosis (<6 years and >6 years post-diagnosis, respectively). Statistical analyses were 
conducted with SPSS v14.
RESULTS
After excluding all potentially curable indolent lymphoma subjects, all those receiving 
chemotherapy, and subjects with aggressive NHL who were not in a remission, 553 subjects 
were included in our analysis (Table 1). Significantly more individuals with indolent NHL 
had advanced stage disease at diagnosis (69% stage III/IV indolent; 45% stage III/IV 
aggressive; p<.001). Additionally, more people with aggressive NHL had received 
chemotherapy (94% vs. 79%, p<0.001) and stem cell transplant (21% vs. 13%, p=0.01).
The aggressive lymphoma survivors reported more distress on the overall score for the 
ALTTIQ (p=.01) with significantly higher score on treatment intensity (p<.001) and past life 
threat (p=.03) but a decreased score on current life threat (p=.01), although the difference on 
the total score differed by only 1.3 points (on a 35 point scale). In terms of the FACT scores, 
survivors with aggressive lymphoma had higher emotional well-being scores (p= .04) than 
did those with indolent lymphoma (0.7 points on 24 point scale). Otherwise, the overall 
QOL on the FACT score between aggressive and indolent lymphoma survivors was similar 
(Table 1), and there also were no significant differences on the positive or negative impact of 
cancer scores.
Differences in QOL between the indolent and aggressive lymphoma groups were greater in 
the short-term survivors (Table 2). Time had a significant relationship to the overall appraisal 
of life threat score (p=.04) and the positive impact of cancer (p=.03). The FACT score also 
significantly related to time since diagnosis (p=.02) with a greater difference in scores for 
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the short term indolent survivors (FACT-G total score 81.20) compared to the aggressive 
survivors (FACT-G total score 88.00). For the long term survivors, the scores were 88.04 and 
87.41, respectively.
DISCUSSION
This manuscript compares QOL in indolent and aggressive NHL survivors, as well as 
differences for short-term versus long-term survivors, to examine whether time related to the 
QOL of these two groups differently. We hypothesized that the incurable nature of indolent 
NHL would relate to worse QOL in long-term survivors, while the potentially cured long-
term survivors of aggressive lymphoma would have better QOL. Our data demonstrate that 
overall, QOL was similar between the indolent and aggressive NHL survivors, other than 
slightly higher appraisal of life threat scores in the aggressive lymphoma survivors. As 
expected, time since diagnosis did significantly relate to difference in some QOL scores 
between the indolent and aggressive NHL. However, unexpectedly, rather than a greater 
difference with increased time since diagnosis, we found the QOL scores between the two 
lymphoma groups were smaller in the long-term follow up group.
The longer-term follow up indolent lymphoma group had higher QOL scores than their 
short-term counterparts, which was the opposite of what we hypothesized; for the overall 
FACT-G, the difference was almost 7 points on a 0–108 scale. It may be that the longer 
people live with their diagnosis of indolent lymphoma, the more adjusted to it they become. 
Those with indolent lymphoma can live for many years without needing treatment as long as 
they remain asymptomatic; consequently, it is likely that individuals who are long-term 
survivors not only have received less aggressive treatment but may have gone many years 
without requiring any treatment. Furthermore, long-term follow up and reports of event free 
survival in several clinical trials demonstrated that the rate of relapse in indolent lymphomas 
is much higher in the first few years after treatment and decreases substantially after 3–4 
years of continued remission (although relapses never completely stop)17,18. Therefore, a 
large number of the long-term survivors may have been in long-term remissions, thereby 
alleviating some of their concerns about their indolent lymphoma and allowing them to live 
more comfortably with uncertainty. For example, long-term survivors of indolent lymphoma 
have probably adapted and developed their coping skills and gained more familiarity with 
the health care setting. However, the higher Appraisal of Life Threat and Treatment Intensity 
scores seen in the longer term indolent lymphoma survivors compared to the short term 
survivors (a 1.4 point difference on a scale of 0–35) suggests that even as subject’s QOL 
improves over time, they continue to be worried about their lymphoma such as risk of 
relapse or need for future chemotherapy.
In contrast, the FACT score for the aggressive NHL subjects is relatively similar between the 
short- and the longer-term follow up groups (a difference of 0.6 points; p>.05), which is not 
surprising since the subjects in the short-term survivor group were all 2–6 years out from 
diagnosis. Individuals with aggressive NHL who are 5 years out from treatment are 
generally considered cured, but since most relapses occur within the first two years, even 
this short-term survivor group might have started to worry less about relapse19. Furthermore, 
by 2 years after diagnosis, most of the side effects from chemotherapy would have resolved 
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or at least stabilized, resulting in fewer differences between the short- and longer-term 
aggressive lymphoma survivors.
Our initial analysis of incurable indolent lymphoma and cured aggressive lymphoma 
survivors included indolent lymphoma subjects who were actively receiving chemotherapy. 
That analysis demonstrated a better QOL in the subjects with aggressive NHL (data not 
shown), but when we excluded the indolent lymphoma survivors receiving chemotherapy, 
most of these differences disappeared, suggesting that some of these differences in QOL 
might have been related to ongoing chemotherapy. By limiting our subject population, we 
not only removed the impact of ongoing chemotherapy, but also some of those with recently 
relapsed disease; it is likely that both of these changes resulted in better QOL scores for this 
subpopulation of the indolent lymphoma group. It has been previously reported that patients 
with relapsed follicular lymphoma, the most common form of indolent lymphoma, have 
inferior health related QOL compared to patients with newly diagnosed follicular lymphoma 
or lymphoma that is in a remission20. Although our decision to examine this subgroup of 
indolent lymphoma individuals makes these results relevant to a smaller group of people, it 
allowed us to remove confounding factors (chemotherapy and active relapse) and thus more 
specifically assess whether simply having an incurable lymphoma relates to poorer QOL 
compared to having a lymphoma that is likely cured.
Our results add to the current body of literature by evaluating the QOL in long term 
survivors who were on average more than 10 years since diagnosis, using data from over 500 
people1,3,4. Blaes and colleagues reported results of two QOL questionnaires (Medical 
Outcomes Study 36-Item Short-form Healthy Survey and the Functional Assessment in 
Cancer Therapy-Fatigue scores) administered to 58 patients with aggressive NHL and 51 
patients with indolent NHL who were at least 1 year out from diagnosis and 3 months from 
most recent chemotherapy4. They found no statistical difference in overall physical and 
mental component QOL scores between survivors of indolent NHL compared to aggressive 
NHL, although there was better physical function in the indolent group. Data from the 
Netherlands looked specifically at fatigue in lymphoma survivors who were a mean of 4.2 
years since diagnosis, and did not find indolent versus aggressive lymphoma to be associated 
with higher fatigue score3. While our data support prior findings that there is no significant 
difference in QOL between individuals with indolent versus aggressive lymphoma, it 
expands on the previously available data by looking at a group much further out from the 
time of diagnosis. Furthermore, our subgroup analysis made an effort to remove 
confounding factors such as ongoing chemotherapy in order to look at the QOL of those 
with indolent lymphoma without potential cure versus those with aggressive lymphoma 
who, in all likelihood, were cured. This strategy allowed us to start to examine the question, 
“Do people with a long-term incurable disease have a worse QOL than those whose disease 
is cured?” Our findings provide increased information about the long-term relationship of 
different lymphoma types on survivor QOL, and demonstrate that people with indolent, 
incurable NHL can have QOL similar to their aggressive lymphoma counterparts.
One of the major limitations of this study is its cross sectional design. Therefore, although 
we looked at short- and longer-term survivor groups, we could not assess how the QOL 
changed for individuals with the passage of time. In addition, although we hypothesized that 
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time since last treatment impacted the QOL responses, we do not have data on when last 
treatment was received and we cannot demonstrate a causal relationship. Lastly, we did not 
administer the questionnaires to healthy people, so we cannot compare the QOL of 
lymphoma to the normal population.
These results are important as they may impact our long-term management of people with 
indolent lymphoma. Patients with indolent lymphoma live for many years, so focusing on 
their QOL is important. It is encouraging that the QOL of patients with indolent lymphoma, 
even when facing the incurable nature of their disease, is overall similar to that seen in 
subjects with aggressive NHL who have been cured.
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